Published 29 days ago

ALS drug Relyvrio withdrawn from market after failed clinical trial

Summary by KRDO

By Mira Cheng, CNN (CNN) — Amylyx Pharmaceuticals announced Thursday that it has begun the process of voluntarily withdrawing its ALS drug, Relyvrio, from the market after it failed to prove efficacy in a large clinical trial. “Relyvrio will no longer be available for new patients as of today. Patients currently on therapy in the US and Canada who, in consultation with their physician, wish to stay on treatment can be transitioned to a free drug…

0 Articles

All

Left

Center

Right

CBC News

ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial

Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.

29 days ago·Canada

Read Full Article

CNN

ALS drug Relyvrio withdrawn from market after failed clinical trial

Amylyx Pharmaceuticals announced Thursday that it has begun the process of voluntarily withdrawing its ALS drug, Relyvrio, from the market after it failed to prove efficacy in a large clinical trial.

29 days ago·Atlanta, United States

Read Full Article

KRDO

ALS drug Relyvrio withdrawn from market after failed clinical trial

29 days ago·Colorado Springs, United States

Read Full Article

KIFI

ALS drug Relyvrio withdrawn from market after failed clinical trial

29 days ago·Idaho Falls, United States

Read Full Article

The Hill

Manufacturer to pull controversial ALS drug off the market after failed clinical trial

The maker of a drug to treat ALS says it will withdraw the medication from the market after it recently failed a large clinical trial.

29 days ago·Washington, United States

Read Full Article

KCRA 3

ALS drug Relyvrio withdrawn from market after failed clinical trial

The pharmaceutical company that produced the drug said it would continue to evaluate and share findings from the clinical trial to help inform future ALS research.

29 days ago·Sacramento, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.